Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: ImmunityBio, Inc. Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 31
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more

Conditions: Malignant Solid Tumour
Interventions: INNO-206; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Bladder Cancer
Interventions: N-803 and BCG, N-803; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 28
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: COVID-19
Interventions: hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline); Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Acute Myeloid Leukemia
Interventions: Graft cell infusion, Tacrolimus, Mycophenolate mofetil, G-CSF, CIML NK cell infusion, ALT-803, Leukapheresis; Procedure · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumors
Interventions: aldoxorubicin; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions: Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: INNO-206; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation); Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2039
U.S. locations: 72
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more

Conditions: Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
Interventions: Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Triple Negative Breast Cancer
Interventions: N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide; Biological · Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: N803 plus Bacillus Calmette-Guerin (BCG); Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: COVID-19
Interventions: hAd5-S-Fusion+N-ETSD vaccine; Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: El Segundo, California • Newport Beach, California

Conditions: HIV Infection
Interventions: N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions: N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab; Drug · Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Newport Beach, California • Tyler, Texas

Conditions: Long COVID
Interventions: N-803 (IL-15 Superagonist); Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Interventions: Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide); Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more

Conditions: NMIBC
Interventions: Intravesical Recombinant Mycobacterium (rMBCG); Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Chandler, Arizona • Sacramento, California • Atlanta, Georgia + 6 more

Conditions: COVID-19
Interventions: N-803, Saline; Biological · Other
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Lynwood, California

Conditions: Non Small Cell Lung Cancer
Interventions: Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin; Drug · Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Long COVID, Long COVID Syndrome, Long Covid 19
Interventions: Anktiva; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: El Segundo, California

Conditions: NSCLC Stage IV
Interventions: N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 32
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • El Segundo, California + 26 more

Conditions: Merkel Cell Carcinoma
Interventions: Avelumab, N-803, haNK™; Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: San Francisco, California • Miami, Florida • St Louis, Missouri + 1 more

Conditions: Covid19
Interventions: hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule); Biological · Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: El Segundo, California • Newport Beach, California

Search by objective public record fields.

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

A Study to Assess Anktiva in Patients With Long Covid-19.

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

A Study to Examine Anktiva for the Treatment of COVID-19.

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA